Page last updated: 2024-11-02

pioglitazone and Heart Defects, Congenital

pioglitazone has been researched along with Heart Defects, Congenital in 2 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Heart Defects, Congenital: Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
García-Beltran, C1
Cereijo, R1
Quesada-López, T1
Malpique, R1
López-Bermejo, A1
de Zegher, F1
Ibáñez, L1
Villarroya, F1
Liu, Y1
Luo, Q1
Su, Z1
Xing, J1
Wu, J1
Xiang, L1
Huang, Y1
Pan, H1
Wu, X1
Zhang, X1
Li, J1
Yan, F1
Zhang, H1

Trials

1 trial available for pioglitazone and Heart Defects, Congenital

ArticleYear
Reduced circulating levels of chemokine CXCL14 in adolescent girls with polycystic ovary syndrome: normalization after insulin sensitization.
    BMJ open diabetes research & care, 2020, Volume: 8, Issue:1

    Topics: Adipocytes; Adipogenesis; Adipose Tissue, Brown; Adolescent; Arrhythmias, Cardiac; Biomarkers; Chemo

2020

Other Studies

1 other study available for pioglitazone and Heart Defects, Congenital

ArticleYear
Suppression of Myocardial Hypoxia-Inducible Factor-1α Compromises Metabolic Adaptation and Impairs Cardiac Function in Patients With Cyanotic Congenital Heart Disease During Puberty.
    Circulation, 2021, 06-08, Volume: 143, Issue:23

    Topics: Animals; Disease Models, Animal; Fatty Acids; Glucose; Glycolysis; Heart Defects, Congenital; Humans

2021